Erik Ingelsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erik Ingelsson has a total of 714 co-authors. Here are the top co-authors by number of shared publications:
Lars Lind
Department of Medical Sciences, Uppsala University, Akademiska sjukhuset, Uppsala, Sweden
8 shared publications- Johan Sundström
Department of Medical Sciences, Uppsala University, Sweden (J.S.).
7 shared publications - Johan Ärnlöv
Karolinska Institutet
7 shared publications Tove Fall
Dept. of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden
5 shared publications- Inga Prokopenko
Department of Clinical & Experimental Medicine, University of Surrey, Guildford GU2 7XH, UK
4 shared publications - Inês Barroso
University of Exeter
4 shared publications
Latest Publications
- 1 October 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36, e115
A1166 Use of proteomics to investigate blood pressure progress in the elderly
Hypertension increases cardiovascular risks. Apart from established clinical risk factors for hypertension, biomarkers were identified as potential risk factors for hypertension but not well-established. We therefore investigated association between cardiovascular proteins and blood pressure (BP) change in prospective cohorts. We used a proteomic profiling approach in two independent cohorts, Prospective Investigation of the Vasculature in Uppsala Seniors study (PIVUS; n = 566, mean age of 70.2 years, 50.4% female) and Uppsala Longitudinal Study of Adult Men (ULSAM; n = 238, mean age of 77.6 years) of elderly individuals at baseline and follow-up data on BP for 5 years. Proteomic chips, which used two antibodies for each protein and a PCR step to achieve a high-specific binding, was measured 92 plasma proteins simultaneously. Malmö Diet and Cancer Study (MDC) was validated the finding. In PIVUS and ULSAM, renin protein significantly predicted BP progression. The odds ratio of renin and BP progression was 1.09 (95% CI, 1.02–1.15; p-value, 0.006) after adjusted for baseline characteristics using mixed models on PIVUS, ULSAM, and MDC cohort. Using linear regression models, the baseline renin level was associated with MAP (mean arterial pressure) change in composite ULSAM and PIVUS cohort (β, 1.21; 95% CI, 0.41 to 2.01), and MDC cohort (β, 0.80; 95% CI, 0.07 to 1.53). However, meta-analysis of three cohorts showed insignificantly associated between renin and MAP change (β, 0.11; 95% CI, −0.10 to 0.33). Using proteomics approach, we discovered and replicated the association between renin protein and BP change but weak associated with BP progression. Further studies are needed to confirm the findings.
- 1 October 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36, e115
A1166 Use of proteomics to investigate blood pressure progress in the elderly
Hypertension increases cardiovascular risks. Apart from established clinical risk factors for hypertension, biomarkers were identified as potential risk factors for hypertension but not well-established. We therefore investigated association between cardiovascular proteins and blood pressure (BP) change in prospective cohorts. We used a proteomic profiling approach in two independent cohorts, Prospective Investigation of the Vasculature in Uppsala Seniors study (PIVUS; n = 566, mean age of 70.2 years, 50.4% female) and Uppsala Longitudinal Study of Adult Men (ULSAM; n = 238, mean age of 77.6 years) of elderly individuals at baseline and follow-up data on BP for 5 years. Proteomic chips, which used two antibodies for each protein and a PCR step to achieve a high-specific binding, was measured 92 plasma proteins simultaneously. Malmö Diet and Cancer Study (MDC) was validated the finding. In PIVUS and ULSAM, renin protein significantly predicted BP progression. The odds ratio of renin and BP progression was 1.09 (95% CI, 1.02–1.15; p-value, 0.006) after adjusted for baseline characteristics using mixed models on PIVUS, ULSAM, and MDC cohort. Using linear regression models, the baseline renin level was associated with MAP (mean arterial pressure) change in composite ULSAM and PIVUS cohort (β, 1.21; 95% CI, 0.41 to 2.01), and MDC cohort (β, 0.80; 95% CI, 0.07 to 1.53). However, meta-analysis of three cohorts showed insignificantly associated between renin and MAP change (β, 0.11; 95% CI, −0.10 to 0.33). Using proteomics approach, we discovered and replicated the association between renin protein and BP change but weak associated with BP progression. Further studies are needed to confirm the findings.
- 1 March 2015
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 3 (3) , 166-167
Use of type 2 diabetes risk scores in clinical practice: a call for action
- 1 March 2015
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 3 (3) , 166-167
Use of type 2 diabetes risk scores in clinical practice: a call for action
- 14 February 2014
- Published by Bentham Science Publishers Ltd. in Current Metabolomics
- Vol. 2 (1) , 27-36
Associations of Body Mass Index and Obesity-Related Genetic Variants with Serum Metabolites
Objectives: Body mass index (BMI) is one of the most important risk factors for different metabolic and cardiovascular disorders. Previously, both genetic and environmental agents associated with BMI have been described. The main focus of this exploratory study was to find the circulating metabolites associated with BMI utilizing an untargeted metabolomics approach. Additionally, significant metabolites identified were studied for their relation with BMIassociated single nucleotide polymorphisms (SNPs). Materials and Methods: A total of 971 individuals from the Cancer of the Prostate in Sweden study (discovery sample- 275 prostate cancers patients and 182 controls; replication sample- 514 prostate cancer patients) were utilized. Blood samples were collected and serum metabolic profiling was obtained using ultra-performance liquid chromatography followed by mass spectrometry. Genotyping data was available for 26 out of 32 SNPs (21 genotyped and 5 proxies) previously robustly associated with BMI in individuals of European descent. Weighted genetic risk score was generated using these SNPs and studied for its association with metabolites. Results: A total of 6138 and 5209 metabolite features were detected in discovery and replication samples, respectively. Out of 6138 metabolite features in discovery sample, 201 were found to be significantly associated with BMI (p-6) after multiple testing correction. These 201 features were further investigated in the replication samples and 16 were found to be significantly associated with BMI (p-4). Seven of these significant features were isotopes for four of the primary metabolites. Four metabolites were putatively identified: monoacylglyceride (18:1), diacylglyrcerol (32:1) and two phosphatidylcholines (34:0 and 36:0). Weighted genetic score of BMI-associated SNPs was not associated with these four metabolites. Conclusion: Four identifiable metabolites (monoacylglyceride, diacyclglyrcerol and two phosphatidylcholines) were found to be significantly associated with BMI in both discovery and replication samples. Common variants associated with BMI did not show association with these four metabolites.
- 14 February 2014
- Published by Bentham Science Publishers Ltd. in Current Metabolomics
- Vol. 2 (1) , 27-36
Associations of Body Mass Index and Obesity-Related Genetic Variants with Serum Metabolites
Objectives: Body mass index (BMI) is one of the most important risk factors for different metabolic and cardiovascular disorders. Previously, both genetic and environmental agents associated with BMI have been described. The main focus of this exploratory study was to find the circulating metabolites associated with BMI utilizing an untargeted metabolomics approach. Additionally, significant metabolites identified were studied for their relation with BMIassociated single nucleotide polymorphisms (SNPs). Materials and Methods: A total of 971 individuals from the Cancer of the Prostate in Sweden study (discovery sample- 275 prostate cancers patients and 182 controls; replication sample- 514 prostate cancer patients) were utilized. Blood samples were collected and serum metabolic profiling was obtained using ultra-performance liquid chromatography followed by mass spectrometry. Genotyping data was available for 26 out of 32 SNPs (21 genotyped and 5 proxies) previously robustly associated with BMI in individuals of European descent. Weighted genetic risk score was generated using these SNPs and studied for its association with metabolites. Results: A total of 6138 and 5209 metabolite features were detected in discovery and replication samples, respectively. Out of 6138 metabolite features in discovery sample, 201 were found to be significantly associated with BMI (p-6) after multiple testing correction. These 201 features were further investigated in the replication samples and 16 were found to be significantly associated with BMI (p-4). Seven of these significant features were isotopes for four of the primary metabolites. Four metabolites were putatively identified: monoacylglyceride (18:1), diacylglyrcerol (32:1) and two phosphatidylcholines (34:0 and 36:0). Weighted genetic score of BMI-associated SNPs was not associated with these four metabolites. Conclusion: Four identifiable metabolites (monoacylglyceride, diacyclglyrcerol and two phosphatidylcholines) were found to be significantly associated with BMI in both discovery and replication samples. Common variants associated with BMI did not show association with these four metabolites.
- 1 January 2014
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 382 (1) , 740-757
Genome-wide association studies of obesity and metabolic syndrome
- 1 January 2014
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 382 (1) , 740-757
Genome-wide association studies of obesity and metabolic syndrome
- 1 September 2013
- Published by Bentham Science Publishers Ltd. in Current Metabolomics
- Vol. 1 (3) , 220-226
Influence of Biological and Technical Covariates on Non-targeted Metabolite Profiling in a Large-scale Epidemiological Study
Non-targeted metabolite profiling using ultra performance liquid chromatography-mass spectrometry (UPLCMS) was performed as part of a large-scale epidemiological study involving biobanked serum samples. The influence of both biological (age and body mass index) and technical (season of sample collection, fasting time, handling time, and storage time) covariates on the analysis was assessed. Statistical models including different sets of these covariates were compared and the results illustrate that variation in which covariates were included did not have an appreciable effect on the number or composition of biologically significant metabolite features associated with body mass index or age. Furthermore, when all covariates were included in the model, there was little overlap of metabolite features significantly associated with the different covariates. Thus, the results of this study illustrate that while some of the observed quantitative variance of metabolite features can be explained by biological and technical covariates, the use of non-targeted metabolite profiling of serum by UPLC-MS is valid for studies of biological outcomes in biobanked clinical samples from large-scale studies.
- 1 September 2013
- Published by Bentham Science Publishers Ltd. in Current Metabolomics
- Vol. 1 (3) , 220-226
Influence of Biological and Technical Covariates on Non-targeted Metabolite Profiling in a Large-scale Epidemiological Study
Non-targeted metabolite profiling using ultra performance liquid chromatography-mass spectrometry (UPLCMS) was performed as part of a large-scale epidemiological study involving biobanked serum samples. The influence of both biological (age and body mass index) and technical (season of sample collection, fasting time, handling time, and storage time) covariates on the analysis was assessed. Statistical models including different sets of these covariates were compared and the results illustrate that variation in which covariates were included did not have an appreciable effect on the number or composition of biologically significant metabolite features associated with body mass index or age. Furthermore, when all covariates were included in the model, there was little overlap of metabolite features significantly associated with the different covariates. Thus, the results of this study illustrate that while some of the observed quantitative variance of metabolite features can be explained by biological and technical covariates, the use of non-targeted metabolite profiling of serum by UPLC-MS is valid for studies of biological outcomes in biobanked clinical samples from large-scale studies.
- Top Cited PapersOpen Access
- 7 April 2013
- Published by Springer Nature in Nature Genetics
- Vol. 45 (5) , 501-512
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture
Erik Ingelsson and colleagues report a large-scale genome-wide meta-analysis for associations to the extremes of anthropometric traits, including body mass index, height, waist-to-hip ratio and clinical obesity. They identify four loci newly associated with height and seven loci newly associated with clinical obesity and find overlap in the genetic structure and distribution of variants identified for these extremes of the trait distributions and for the general population. Approaches exploiting trait distribution extremes may be used to identify loci associated with common traits, but it is unknown whether these loci are generalizable to the broader population. In a genome-wide search for loci associated with the upper versus the lower 5th percentiles of body mass index, height and waist-to-hip ratio, as well as clinical classes of obesity, including up to 263,407 individuals of European ancestry, we identified 4 new loci (IGFBP4, H6PD, RSRC1 and PPP2R2A) influencing height detected in the distribution tails and 7 new loci (HNF4G, RPTOR, GNAT2, MRPS33P4, ADCY9, HS6ST3 and ZZZ3) for clinical classes of obesity. Further, we find a large overlap in genetic structure and the distribution of variants between traits based on extremes and the general population and little etiological heterogeneity between obesity subgroups.
- 7 April 2013
- Published by Springer Nature in Nature Genetics
- Vol. 45 (5) , 501-512
Top Cited PapersOpen AccessGenome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture
Erik Ingelsson and colleagues report a large-scale genome-wide meta-analysis for associations to the extremes of anthropometric traits, including body mass index, height, waist-to-hip ratio and clinical obesity. They identify four loci newly associated with height and seven loci newly associated with clinical obesity and find overlap in the genetic structure and distribution of variants identified for these extremes of the trait distributions and for the general population. Approaches exploiting trait distribution extremes may be used to identify loci associated with common traits, but it is unknown whether these loci are generalizable to the broader population. In a genome-wide search for loci associated with the upper versus the lower 5th percentiles of body mass index, height and waist-to-hip ratio, as well as clinical classes of obesity, including up to 263,407 individuals of European ancestry, we identified 4 new loci (IGFBP4, H6PD, RSRC1 and PPP2R2A) influencing height detected in the distribution tails and 7 new loci (HNF4G, RPTOR, GNAT2, MRPS33P4, ADCY9, HS6ST3 and ZZZ3) for clinical classes of obesity. Further, we find a large overlap in genetic structure and the distribution of variants between traits based on extremes and the general population and little etiological heterogeneity between obesity subgroups.
- Open Access
- 14 March 2013
- Published by American Diabetes Association in Diabetes
- Vol. 62 (4) , 1338-1344
Evidence of a Causal Relationship Between Adiponectin Levels and Insulin Sensitivity
The adipocyte-secreted protein adiponectin is associated with insulin sensitivity in observational studies. We aimed to evaluate whether this relationship is causal using a Mendelian randomization approach. In a sample of Swedish men aged 71 years (n = 942) from the Uppsala Longitudinal Study of Adult Men (ULSAM), insulin sensitivity (M/I ratio) was measured by the euglycemic insulin clamp. We used three genetic variants in the ADIPOQ locus as instrumental variables (IVs) to estimate the potential causal effect of adiponectin on insulin sensitivity and compared these with results from conventional linear regression. The three ADIPOQ variants, rs17300539, rs3774261, and rs6444175, were strongly associated with serum adiponectin levels (all P ≤ 5.3 × 10−9) and were also significantly associated with M/I ratio in the expected direction (all P ≤ 0.022). IV analysis confirmed that genetically determined adiponectin increased insulin sensitivity (β = 0.47–0.81, all P ≤ 0.014) comparable with observational estimates (β = 0.50, all Pdifference ≥ 0.136). Adjustment for BMI and waist circumference partly explained the association of both genetically determined and observed adiponectin levels with insulin sensitivity. The observed association between higher adiponectin levels and increased insulin sensitivity is likely to represent a causal relationship partly mediated by reduced adiposity.
- 14 March 2013
- Published by American Diabetes Association in Diabetes
- Vol. 62 (4) , 1338-1344
Open AccessEvidence of a Causal Relationship Between Adiponectin Levels and Insulin Sensitivity
The adipocyte-secreted protein adiponectin is associated with insulin sensitivity in observational studies. We aimed to evaluate whether this relationship is causal using a Mendelian randomization approach. In a sample of Swedish men aged 71 years (n = 942) from the Uppsala Longitudinal Study of Adult Men (ULSAM), insulin sensitivity (M/I ratio) was measured by the euglycemic insulin clamp. We used three genetic variants in the ADIPOQ locus as instrumental variables (IVs) to estimate the potential causal effect of adiponectin on insulin sensitivity and compared these with results from conventional linear regression. The three ADIPOQ variants, rs17300539, rs3774261, and rs6444175, were strongly associated with serum adiponectin levels (all P ≤ 5.3 × 10−9) and were also significantly associated with M/I ratio in the expected direction (all P ≤ 0.022). IV analysis confirmed that genetically determined adiponectin increased insulin sensitivity (β = 0.47–0.81, all P ≤ 0.014) comparable with observational estimates (β = 0.50, all Pdifference ≥ 0.136). Adjustment for BMI and waist circumference partly explained the association of both genetically determined and observed adiponectin levels with insulin sensitivity. The observed association between higher adiponectin levels and increased insulin sensitivity is likely to represent a causal relationship partly mediated by reduced adiposity.
- Open Access
- 27 September 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 537
Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study
The role of inflammation and oxidative stress in mild renal impairment in the elderly is not well studied. Accordingly, we aimed at investigating the associations between estimated glomerular filtration rate (eGFR), albumin/creatinine ratio (ACR), and markers of different inflammatory pathways and oxidative stress in a community based cohort of elderly men. Cystatin C-based GFR, ACR, and biomarkers of cytokine-mediated inflammation (interleukin-6, high-sensitivity C-reactive protein[CRP], serum amyloid A[SAA]), cyclooxygenase-mediated inflammation (urinary prostaglandin F2α [PGF2α]), and oxidative stress (urinary F2 isoprostanes) were assessed in the Uppsala Longitudinal Study of Adult Men(n = 647, mean age 77 years). In linear regression models adjusting for age, BMI, smoking, blood pressure, LDL-cholesterol, HDL-cholesterol, triglycerides, and treatment with statins, ACE-inhibitors, ASA, and anti-inflammatory agents, eGFR was inversely associated with CRP, interleukin-6, and SAA (β-coefficient -0.13 to -0.19, p < 0.001 for all), and positively associated with urinary F2-isoprostanes (β-coefficient 0.09, p = 0.02). In line with this, ACR was positively associated with CRP, interleukin-6, and SAA (β- coefficient 0.09-0.12, p < 0.02 for all), and negatively associated with urinary F2-isoprostanes (β-coefficient -0.12, p = 0.002). The associations were similar but with lower regression coefficients in a sub-sample with normal eGFR (>60 ml/min/1.73 m2, n = 514), with the exception that F2-isoprostane and SAA were no longer associated with eGFR. Our data indicate that cytokine-mediated inflammation is involved in the early stages of impaired kidney function in the elderly, but that cyclooxygenase-mediated inflammation does not play a role at this stage. The unexpected association between higher eGFR/lower albuminuria and increased F2-isoprostanes in urine merits further studies.
- 27 September 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 537
Open AccessInflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: a cross-sectional study
The role of inflammation and oxidative stress in mild renal impairment in the elderly is not well studied. Accordingly, we aimed at investigating the associations between estimated glomerular filtration rate (eGFR), albumin/creatinine ratio (ACR), and markers of different inflammatory pathways and oxidative stress in a community based cohort of elderly men. Cystatin C-based GFR, ACR, and biomarkers of cytokine-mediated inflammation (interleukin-6, high-sensitivity C-reactive protein[CRP], serum amyloid A[SAA]), cyclooxygenase-mediated inflammation (urinary prostaglandin F2α [PGF2α]), and oxidative stress (urinary F2 isoprostanes) were assessed in the Uppsala Longitudinal Study of Adult Men(n = 647, mean age 77 years). In linear regression models adjusting for age, BMI, smoking, blood pressure, LDL-cholesterol, HDL-cholesterol, triglycerides, and treatment with statins, ACE-inhibitors, ASA, and anti-inflammatory agents, eGFR was inversely associated with CRP, interleukin-6, and SAA (β-coefficient -0.13 to -0.19, p < 0.001 for all), and positively associated with urinary F2-isoprostanes (β-coefficient 0.09, p = 0.02). In line with this, ACR was positively associated with CRP, interleukin-6, and SAA (β- coefficient 0.09-0.12, p < 0.02 for all), and negatively associated with urinary F2-isoprostanes (β-coefficient -0.12, p = 0.002). The associations were similar but with lower regression coefficients in a sub-sample with normal eGFR (>60 ml/min/1.73 m2, n = 514), with the exception that F2-isoprostane and SAA were no longer associated with eGFR. Our data indicate that cytokine-mediated inflammation is involved in the early stages of impaired kidney function in the elderly, but that cyclooxygenase-mediated inflammation does not play a role at this stage. The unexpected association between higher eGFR/lower albuminuria and increased F2-isoprostanes in urine merits further studies.
- 1 September 2012
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (9) , 985-991
Relations of Circulating Vitamin D Concentrations with Left Ventricular Geometry and Function
Aims: Vitamin D deficiency has been associated with risk of overt cardiovascular disease (CVD), but associations with subclinical disease are not well characterized. Hence, we examined associations of circulating vitamin D concentrations and left ventricular (LV) geometry and function by echocardiography at baseline and after 5 years in a community-based study. Methods and results: In the PIVUS study, we measured serum 25-dihydroxyvitamin-D (25-OH D) at age 70 and performed echocardiography including LV mass, wall thickness, end-diastolic diameter, end-systolic diameter (LVESD), left atrial diameter, fractional shortening, ejection fraction, isovolumic relaxation time, and E/A ratio at both age 70 and 75. We included 870 participants (52% women) without prior myocardial infarctions, heart failure, or prevalent valvular disease. After adjusting for potential confounders, 25-OH D at baseline was found to be significantly associated with LVESD, fractional shortening, and ejection fraction (β, –0.42 mm, P = 0.03; β, 0.70%, P = 0.03; and β, 0.91% P = 0.01, respectively), per 1 SD increase in 25-OH D (SD = 20 nmol/L) at baseline. In longitudinal analyses, vitamin D levels at baseline were not significantly associated with change in LV geometry and function after 5 years. Conclusion: In our community-based study among the elderly, we found higher circulating vitamin D concentrations to be associated cross-sectionally with better LV systolic function and smaller LVESD at baseline. The association persisted after adjusting for several potential confounders, including cardiovascular risk factors and calcium, phosphate, and parathyroid hormone levels. Randomized clinical trials are needed to establish firmly or refute a causal relationship between vitamin D levels and changes in LV geometry and function.
- 1 September 2012
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (9) , 985-991
Relations of Circulating Vitamin D Concentrations with Left Ventricular Geometry and Function
Aims: Vitamin D deficiency has been associated with risk of overt cardiovascular disease (CVD), but associations with subclinical disease are not well characterized. Hence, we examined associations of circulating vitamin D concentrations and left ventricular (LV) geometry and function by echocardiography at baseline and after 5 years in a community-based study. Methods and results: In the PIVUS study, we measured serum 25-dihydroxyvitamin-D (25-OH D) at age 70 and performed echocardiography including LV mass, wall thickness, end-diastolic diameter, end-systolic diameter (LVESD), left atrial diameter, fractional shortening, ejection fraction, isovolumic relaxation time, and E/A ratio at both age 70 and 75. We included 870 participants (52% women) without prior myocardial infarctions, heart failure, or prevalent valvular disease. After adjusting for potential confounders, 25-OH D at baseline was found to be significantly associated with LVESD, fractional shortening, and ejection fraction (β, –0.42 mm, P = 0.03; β, 0.70%, P = 0.03; and β, 0.91% P = 0.01, respectively), per 1 SD increase in 25-OH D (SD = 20 nmol/L) at baseline. In longitudinal analyses, vitamin D levels at baseline were not significantly associated with change in LV geometry and function after 5 years. Conclusion: In our community-based study among the elderly, we found higher circulating vitamin D concentrations to be associated cross-sectionally with better LV systolic function and smaller LVESD at baseline. The association persisted after adjusting for several potential confounders, including cardiovascular risk factors and calcium, phosphate, and parathyroid hormone levels. Randomized clinical trials are needed to establish firmly or refute a causal relationship between vitamin D levels and changes in LV geometry and function.
- Top Cited PapersOpen Access
- 12 August 2012
- Published by Springer Nature in Nature Genetics
- Vol. 44 (9) , 991-1005
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways
Jose Florez, Claudia Langenberg, Erik Ingelsson, Inga Prokopenko, Inês Barroso and colleagues perform large-scale association analyses using the Metabochip to gain further insights into the genetic architecture of glucose regulation. They identify 38 new loci influencing 1 or more glycemic traits and show that many of these loci also modify risk of type 2 diabetes. Through genome-wide association meta-analyses of up to 133,010 individuals of European ancestry without diabetes, including individuals newly genotyped using the Metabochip, we have increased the number of confirmed loci influencing glycemic traits to 53, of which 33 also increase type 2 diabetes risk (q < 0.05). Loci influencing fasting insulin concentration showed association with lipid levels and fat distribution, suggesting impact on insulin resistance. Gene-based analyses identified further biologically plausible loci, suggesting that additional loci beyond those reaching genome-wide significance are likely to represent real associations. This conclusion is supported by an excess of directionally consistent and nominally significant signals between discovery and follow-up studies. Functional analysis of these newly discovered loci will further improve our understanding of glycemic control.
- 12 August 2012
- Published by Springer Nature in Nature Genetics
- Vol. 44 (9) , 991-1005
Top Cited PapersOpen AccessLarge-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways
Jose Florez, Claudia Langenberg, Erik Ingelsson, Inga Prokopenko, Inês Barroso and colleagues perform large-scale association analyses using the Metabochip to gain further insights into the genetic architecture of glucose regulation. They identify 38 new loci influencing 1 or more glycemic traits and show that many of these loci also modify risk of type 2 diabetes. Through genome-wide association meta-analyses of up to 133,010 individuals of European ancestry without diabetes, including individuals newly genotyped using the Metabochip, we have increased the number of confirmed loci influencing glycemic traits to 53, of which 33 also increase type 2 diabetes risk (q < 0.05). Loci influencing fasting insulin concentration showed association with lipid levels and fat distribution, suggesting impact on insulin resistance. Gene-based analyses identified further biologically plausible loci, suggesting that additional loci beyond those reaching genome-wide significance are likely to represent real associations. This conclusion is supported by an excess of directionally consistent and nominally significant signals between discovery and follow-up studies. Functional analysis of these newly discovered loci will further improve our understanding of glycemic control.